Sanjay Kumar, MD
Internal Medicine · Port Charlotte, FLNPI 1669585378
Payments from drug & device makers
Across 222 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$949
- GSK$639
- Bayer$597
- Boston Scientific$356
- Amgen$249
- Actelion Pharmaceuticals US, Inc.$226
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,316100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $949 |
| GSK | 29 | $639 |
| Bayer | 17 | $597 |
| Boston Scientific | 5 | $356 |
| Amgen | 13 | $249 |
| Actelion Pharmaceuticals US, Inc. | 2 | $226 |
| GE HealthCare | 13 | $201 |
| Abbott | 5 | $200 |
| Pfizer | 9 | $171 |
| Boehringer Ingelheim | 7 | $152 |
| Lilly USA, LLC | 6 | $141 |
| Johnson & Johnson | 4 | $130 |
| Dexcom, Inc. | 3 | $128 |
| Pharming Healthcare, Inc. | 1 | $124 |
| Novo Nordisk | 6 | $101 |
| AstraZeneca | 2 | $91 |
| Amarin Pharma, Inc. | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Merck | 4 | $65 |
| Sunovion Pharmaceuticals Inc. | 5 | $65 |
| Eisai Inc. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $46 |
| UCB, Inc. | 2 | $43 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Redhill Biopharma Inc. | 2 | $30 |
| Exact Sciences | 1 | $30 |
| Cook Medical LLC | 1 | $28 |
| Novartis | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Inari Medical, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,316 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $135,791 |
| JardianceEmpagliflozin | 89 | $119,710 |
| EliquisApixaban | 63 | $86,447 |
| FarxigaDapagliflozin Propanediol | 52 | $75,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $66,523 |
| JanuviaSitagliptin Phosphate | 45 | $59,108 |
| TrulicityDulaglutide | 17 | $40,205 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $31,431 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $24,277 |
| GlyxambiEmpagliflozin/Linagliptin | 19 | $22,731 |
| XareltoRivaroxaban | 20 | $22,560 |
| Repatha SureclickEvolocumab | 14 | $15,284 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $14,240 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $12,358 |
| MyrbetriqMirabegron | 15 | $11,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $152 | $142,441108 claims |
| Novo NordiskOzempic | $101 | $135,79181 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $639 | $93,12190 claims |
| PfizerEliquis | $171 | $86,44763 claims |
| MerckJanuvia, Janumet | $65 | $83,38560 claims |
| AstraZenecaFarxiga | $91 | $75,43952 claims |
| Lilly USA, LLCTrulicity | $141 | $40,20517 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $48 | $31,43117 claims |
| Johnson & JohnsonXarelto | $130 | $22,56020 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $11,53015 claims |
| AbbVieSynthroid | $949 | $1,22326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Port Charlotte
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.